Investigational Drug Details
| Drug ID: | D437 |
| Drug Name: | Iodine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB05382 |
| DrugBank Description: | Molecualar iodine has been developed by Symbollon Pharmaceuticals. It is a potential treatment for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD). |
| PubChem ID: | 807 |
| CasNo: | 7553-56-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | II |
| Structure: |
|
| InChiKey: | PNDPGZBMCMUPRI-UHFFFAOYSA-N |
| Molecular Weight: | 253.8089 |
| DrugBank Targets: | Sodium/iodide cotransporter; NA |
| DrugBank MoA: | Molecular iodine is known to inhibit the induction and promotion of N-methyl-n-nitrosourea-induced mammary carcinogenesis, to regress 7,12-dimethylbenz(a)anthracene-induced breast tumors in rats.It has also been shown to have beneficial effects in fibrocystic human breast disease. |
| DrugBank Pharmacology: | |
| DrugBank Indication: | Investigated for use/treatment in breast disorders (unspecified) and pain (acute or chronic). |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L5195 | NCT02886884 | PHASE1|PHASE2 | COMPLETED | YES | 2017-10-20 | 2022-05-11 | Details |
| L5584 | NCT00423215 | COMPLETED | NO | 2006-03 | 2009-06-15 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|